Cystic fibrosis: comorbidity with other serious diseases
暂无分享,去创建一个
V. Zhelev | Y. Rafikova | E. Loshkova | E. Kondratieva | A. Khavkin | N. D. Odinaeva | V. K. Prudnikova | G. N. Yankina | I. V. Doroshenko | T. S. Liulka | M. V. Rebrienko | E. A. Bozhenko
[1] H. Gavillet,et al. Bacterial Culture Underestimates Lung Pathogen Detection and Infection Status in Cystic Fibrosis , 2022, Microbiology spectrum.
[2] L. Decosterd,et al. Therapeutic Drug Monitoring of Ivacaftor, Lumacaftor, Tezacaftor, and Elexacaftor in Cystic Fibrosis: Where Are We Now? , 2022, Pharmaceutics.
[3] T. Sferra,et al. Epidemiology of Eosinophilic Esophagitis in Patients with Cystic Fibrosis: A Population-Based 5-Year Study , 2022, Pediatric gastroenterology, hepatology & nutrition.
[4] D. Sanders,et al. Nomenclature and diagnosis of seronegative coeliac disease and chronic non-coeliac enteropathies in adults: the Paris consensus , 2022, Gut.
[5] A. Gala-Błądzińska,et al. Renal Function in Patients with Cystic Fibrosis: A Single-Center Study , 2022, International journal of environmental research and public health.
[6] S. Almeida,et al. Faecal calprotectin and rectal histological inflammatory markers in cystic fibrosis: a single-centre study , 2022, BMJ Paediatrics Open.
[7] I. Esposito,et al. CFTR Modulator Therapies: Potential Impact on Airway Infections in Cystic Fibrosis , 2022, Cells.
[8] G. Deslée,et al. Prevalence and Impact of Rheumatologic Pain in Cystic Fibrosis Adult Patients , 2022, Frontiers in Medicine.
[9] C. Y. Ooi,et al. What Do We Know about the Microbiome in Cystic Fibrosis? Is There a Role for Probiotics and Prebiotics? , 2022, Nutrients.
[10] H. Ellemunter,et al. Malignancies in patients with cystic fibrosis: a case series , 2022, Journal of Medical Case Reports.
[11] P. Maisonneuve,et al. Cancer in Cystic Fibrosis: A Narrative Review of Prevalence, Risk Factors, Screening and Treatment Challenges. , 2021, Chest.
[12] P. Hegyi,et al. Increased Prevalence of Celiac Disease in Patients with Cystic Fibrosis: A Systematic Review and Meta-Analysis , 2021, Journal of personalized medicine.
[13] P. Cullinan,et al. Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case-control study. , 2021, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[14] L. Marciani,et al. Magnetic resonance imaging of the gastrointestinal tract shows reduced small bowel motility and altered chyme in cystic fibrosis compared to controls , 2021, medRxiv.
[15] D. Goldfarb,et al. Urinary stone disease prevalence and associations in cystic fibrosis , 2021, Urolithiasis.
[16] M. Zali,et al. Prevalence of celiac disease in low and high risk population in Asia–Pacific region: a systematic review and meta-analysis , 2021, Scientific Reports.
[17] Jianfeng Xu,et al. Cystic fibrosis F508del carriers and cancer risk: Results from the UK Biobank , 2020, International journal of cancer.
[18] C. Siva,et al. Rheumatoid arthritis in a patient with cystic fibrosis: challenging treatment options , 2020, BMJ Case Reports.
[19] M. Zali,et al. An updated overview of spectrum of gluten-related disorders: clinical and diagnostic aspects , 2020, BMC Gastroenterology.
[20] P. Palange,et al. Renal involvement and metabolic alterations in adults patients affected by cystic fibrosis , 2019, Journal of Translational Medicine.
[21] H. Green,et al. 24. Chronic inflammatory arthritis in the context of cystic fibrosis , 2019, Rheumatology Advances in Practice.
[22] G. Kroemer,et al. Cystic fibrosis transmembrane conductance regulator (CFTR) and autophagy: hereditary defects in cystic fibrosis versus gluten-mediated inhibition in celiac disease , 2019, Oncotarget.
[23] C. Lightdale,et al. Cystic fibrosis is associated with an increased risk of Barrett's esophagus. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[24] M. Nikolski,et al. Intestinal Inflammation in Children with Cystic Fibrosis Is Associated with Crohn’s-Like Microbiota Disturbances , 2019, Journal of clinical medicine.
[25] D. Sanders,et al. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders , 2019, United European gastroenterology journal.
[26] G. Kroemer,et al. Genistein antagonizes gliadin-induced CFTR malfunction in models of celiac disease , 2019, Aging.
[27] M. Walshaw,et al. Evaluation of Gastric Emptying in Cystic Fibrosis Using Bedside Ultrasonography , 2019, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.
[28] G. Kroemer,et al. The gliadin-CFTR connection: new perspectives for the treatment of celiac disease , 2019, Italian Journal of Pediatrics.
[29] M. Ramírez,et al. Crohns disease and cystic fibrosis: there is still a lot to learn , 2018 .
[30] P. H. Green,et al. Global Prevalence of Celiac Disease: Systematic Review and Meta‐analysis , 2018, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[31] A. Zauber,et al. Cystic Fibrosis Colorectal Cancer Screening Consensus Recommendations. , 2017, Gastroenterology.
[32] L. Ryom,et al. Prevalence and characteristics of chronic kidney disease among Danish adults with cystic fibrosis. , 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[33] M. Putman,et al. Celiac Disease in Patients with Cystic Fibrosis-Related Bone Disease , 2017, Case reports in endocrinology.
[34] Vikesh K. Singh,et al. Pancreatic insufficiency in Cystic Fibrosis. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[35] M. Haupt,et al. The role of small intestinal bacterial overgrowth in cystic fibrosis: a randomized case-controlled clinical trial with rifaximin , 2017, Journal of gastroenterology.
[36] C. Y. Ooi,et al. The Enigmatic Gut in Cystic Fibrosis: Linking Inflammation, Dysbiosis, and the Increased Risk of Malignancy , 2017, Current Gastroenterology Reports.
[37] S. Gangloff,et al. Bone disease in cystic fibrosis: new pathogenic insights opening novel therapies , 2016, Osteoporosis International.
[38] J. Bai,et al. Bone and Celiac Disease , 2016, Current Osteoporosis Reports.
[39] C. Gallagher,et al. Infliximab is safe and induces sustained remission with complete mucosal healing in Crohn's disease in a patient with pan resistant pseudomonas cystic fibrosis: a case report. , 2014, Journal of Crohn's & colitis.
[40] Emily A. Knapp,et al. Cancer risk in cystic fibrosis: a 20-year nationwide study from the United States. , 2013, Journal of the National Cancer Institute.
[41] R. Medzhitov,et al. Abnormal Trafficking and Degradation of TLR4 Underlie the Elevated Inflammatory Response in Cystic Fibrosis , 2011, The Journal of Immunology.
[42] Nikolina Zdraveska,et al. Coagulopathy as initial manifestation of concomitant celiac disease and cystic fibrosis: a case report , 2011, Journal of medical case reports.
[43] J. Walkowiak,et al. Cystic fibrosis is a risk factor for celiac disease. , 2010, Acta biochimica Polonica.
[44] G. Lenoir,et al. In Cystic Fibrosis Homozygotes and Heterozygotes, Neutrophil Apoptosis Is Delayed and Modulated by Diamide or Roscovitine: Evidence for an Innate Neutrophil Disturbance , 2010, Journal of Innate Immunity.
[45] T. Pressler,et al. Co-morbidity of cystic fibrosis and celiac disease in Scandinavian cystic fibrosis patients. , 2009, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[46] P. Miossec. IL-17 and Th17 cells in human inflammatory diseases. , 2009, Microbes and infection.
[47] E. Chilvers,et al. Prolonged survival of neutrophils from patients with ΔF508 CFTR mutations , 2008, Thorax.
[48] E. Aktas,et al. Prevalence of Celiac Disease in Turkish Children , 2005, Journal of clinical gastroenterology.
[49] J. Kolls,et al. Role of IL-17A, IL-17F, and the IL-17 Receptor in Regulating Growth-Related Oncogene-α and Granulocyte Colony-Stimulating Factor in Bronchial Epithelium: Implications for Airway Inflammation in Cystic Fibrosis 1 , 2005, The Journal of Immunology.
[50] V. Raia,et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration , 2004, Alimentary pharmacology & therapeutics.
[51] D. Hume,et al. G551D Cystic Fibrosis Mice Exhibit Abnormal Regulation of Inflammation in Lungs and Macrophages1 , 2000, The Journal of Immunology.
[52] K. Bendtzen,et al. Cytokines in sputum and serum from patients with cystic fibrosis and chronic pseudomonas aeruginosa infection as markers of destructive inflammation in the lungs. , 1993, Pediatric pulmonology.
[53] S. Freedman,et al. Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages. , 2008, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.